CK2 Inhibitors – New CK2 Kinase Inhibitors for antineoplastic drugs and diagnostics

Beside cardiovascular diseases, malignant tumours take

the second place in cause of human death. Neoplastic diseases are indicated by a high cell proliferation. The inhibition of this cell proliferation by an active agent in a medicament is a worldwide accepted approach for tumour therapy. Protein kinase CK2 belongs together with others to the group of second-messenger independent kinases. Despite of unambiguous references for the involvement of CK2 in malignant transformation, tumour origin and progression, there are only a few effective inhibitors for this enzyme on-hand. This invention provides access to a novel class of potent human CK2 kinase inhibitors. The disclosed compounds can be used as active ingredients e.g. for the treatment of neoplastic diseases. Further, the patent application discloses synthesis of the compounds with optimised product yield.

Further Information: PDF

PROvendis GmbH
Phone: +49 (0)208/94105 10

Contact
Dipl.-Ing. Alfred Schillert

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Future AR/VR controllers could be the palm of your hand

Carnegie Mellon University’s EgoTouch creates simple interfaces for virtual and augmented reality. The new generation of augmented and virtual reality controllers may not just fit in the palm of your…

‘Game changer’ in lithium extraction

Rice researchers develop novel electrochemical reactor. A team of Rice University researchers led by Lisa Biswal and Haotian Wang has developed an innovative electrochemical reactor to extract lithium from natural…

The blue-green sustainable proteins of seaweed

… may soon be on your plate. The protein in sea lettuce, a type of seaweed, is a promising complement to both meat and other current alternative protein sources. Seaweed…